Halozyme Therapeutics vs Sarepta Therapeutics
Sarepta Therapeutics is the larger business, with $2.20bn of revenue in fiscal 2025 against $1.40bn for Halozyme Therapeutics (1.6 times as much). Halozyme Therapeutics grew faster (37.6% against 15.6%). Halozyme Therapeutics kept more of each dollar of sales as profit: a net margin of 22.7% against -32.5%.
| Latest fiscal year | Halozyme TherapeuticsHALO, 2025 | Sarepta TherapeuticsSRPT, 2025 |
|---|---|---|
| Revenue | $1.40bn | $2.20bn |
| Revenue growth | 37.6% | 15.6% |
| Net income | $317m | −$713m |
| Operating margin | — | -31.8% |
| Net margin | 22.7% | -32.5% |
| Return on equity | 153.6% | -53.5% |
| Free cash flow | $645m | −$307m |
| Cash | $134m | $801m |
| Total debt | $2.18bn | $829m |
| Debt to equity | — | 72.7% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $342m | $25.0m |
| Employees | 423 | 835 |
| Market value | $14.77bn | $1.96bn |
| Price vs our value range | Below our value range | — |
| Moat score | 71 (Strong) | 10 (Weak) |
| Insider trades, 12 months | 0 buys, 105 sales | 0 buys, 2 sales |